Catalysts in Science
At the 2026 JPM Conference in San Francisco, Astellas President and CEO Naoki Okamura spoke with STAT Brand Studio Editor Jesse McQuarters about the company’s strategy and long-term vision as it enters an important phase in the company’s evolution. Astellas is taking a patient-centered approach and investing in four key areas within R&D — targeted protein degradation, immuno-oncology, blindness and regeneration, and genetic regulation — as it prepares for the loss of exclusivity of its leading prostate cancer therapy. Read more here: https://www.statnews.com/sponsor/2026/02/23/astellas-ceo-talks-transformative-medicines-driving-growth/
15 jaksot
Kommentit
0Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity Catalysts in Science-yhteisöön!